Angioimmunoblastic T-Cell Lymphoma Management

Kailash Mosalpuria, Robert G Bociek, Julie Marie Vose

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Angioimmunoblastic T-cell lymphoma (AITL) is a frequent subtype of peripheral T-cell lymphoma (PTCL) that is clinically characterized by generalized lymphadenopathy, extranodal involvement, advanced stage at presentation, hypergammaglobulinemia, and significant immune dysregulation resulting in infections as the most common cause of death. Recent advances in pathobiology of AITL have improved our understanding of it as a clonal T-cell disorder and of its effect on B cells in the tumor microenvironment. Reponses to first-line therapies have largely been dismal. In this review, we discuss the clinical features, pathobiology, prognostic models, standard therapy, and newer therapeutic agents used and their implications for the future.

Original languageEnglish (US)
Pages (from-to)52-58
Number of pages7
JournalSeminars in hematology
Volume51
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Hypergammaglobulinemia
Tumor Microenvironment
Cause of Death
B-Lymphocytes
Therapeutics
T-Lymphocytes
Infection

ASJC Scopus subject areas

  • Hematology

Cite this

Angioimmunoblastic T-Cell Lymphoma Management. / Mosalpuria, Kailash; Bociek, Robert G; Vose, Julie Marie.

In: Seminars in hematology, Vol. 51, No. 1, 01.01.2014, p. 52-58.

Research output: Contribution to journalArticle

@article{425aabdd15a34e12a89b357b4099d983,
title = "Angioimmunoblastic T-Cell Lymphoma Management",
abstract = "Angioimmunoblastic T-cell lymphoma (AITL) is a frequent subtype of peripheral T-cell lymphoma (PTCL) that is clinically characterized by generalized lymphadenopathy, extranodal involvement, advanced stage at presentation, hypergammaglobulinemia, and significant immune dysregulation resulting in infections as the most common cause of death. Recent advances in pathobiology of AITL have improved our understanding of it as a clonal T-cell disorder and of its effect on B cells in the tumor microenvironment. Reponses to first-line therapies have largely been dismal. In this review, we discuss the clinical features, pathobiology, prognostic models, standard therapy, and newer therapeutic agents used and their implications for the future.",
author = "Kailash Mosalpuria and Bociek, {Robert G} and Vose, {Julie Marie}",
year = "2014",
month = "1",
day = "1",
doi = "10.1053/j.seminhematol.2013.11.008",
language = "English (US)",
volume = "51",
pages = "52--58",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Angioimmunoblastic T-Cell Lymphoma Management

AU - Mosalpuria, Kailash

AU - Bociek, Robert G

AU - Vose, Julie Marie

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Angioimmunoblastic T-cell lymphoma (AITL) is a frequent subtype of peripheral T-cell lymphoma (PTCL) that is clinically characterized by generalized lymphadenopathy, extranodal involvement, advanced stage at presentation, hypergammaglobulinemia, and significant immune dysregulation resulting in infections as the most common cause of death. Recent advances in pathobiology of AITL have improved our understanding of it as a clonal T-cell disorder and of its effect on B cells in the tumor microenvironment. Reponses to first-line therapies have largely been dismal. In this review, we discuss the clinical features, pathobiology, prognostic models, standard therapy, and newer therapeutic agents used and their implications for the future.

AB - Angioimmunoblastic T-cell lymphoma (AITL) is a frequent subtype of peripheral T-cell lymphoma (PTCL) that is clinically characterized by generalized lymphadenopathy, extranodal involvement, advanced stage at presentation, hypergammaglobulinemia, and significant immune dysregulation resulting in infections as the most common cause of death. Recent advances in pathobiology of AITL have improved our understanding of it as a clonal T-cell disorder and of its effect on B cells in the tumor microenvironment. Reponses to first-line therapies have largely been dismal. In this review, we discuss the clinical features, pathobiology, prognostic models, standard therapy, and newer therapeutic agents used and their implications for the future.

UR - http://www.scopus.com/inward/record.url?scp=84892889160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892889160&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2013.11.008

DO - 10.1053/j.seminhematol.2013.11.008

M3 - Article

C2 - 24468316

AN - SCOPUS:84892889160

VL - 51

SP - 52

EP - 58

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 1

ER -